The short answer
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It combines tuftsin, an immunomodulatory tetrapeptide from immunoglobulin G, with a Pro-Gly-Pro extension that confers resistance to enzymatic degradation.
Key facts
- Sequence
- Thr-Lys-Pro-Arg-Pro-Gly-Pro
- Single-letter
- TKPRPGP
- Length
- 7 residues (heptapeptide)
- Molecular weight
- 751.9 Da
- Molecular formula
- C33H57N11O9
- CAS number
- 129954-34-3
- PubChem CID
- 11765600
- Development code
- TP-7
- Western approval
- None (not MHRA, EMA or FDA approved)
What it is built from
The Selank peptide has two parts. The first four residues, Thr-Lys-Pro-Arg, are tuftsin, a naturally occurring tetrapeptide released from the heavy chain of immunoglobulin G and long studied for immunomodulatory activity. The remaining three, Pro-Gly-Pro, are a stabilising extension. The design intent is to retain tuftsin's activity while giving it a useful duration in circulation.
Why the extension was necessary
Tuftsin on its own is degraded rapidly. Proline-containing motifs resist most peptidases, because proline's side chain bonds back to its own backbone nitrogen and locks the rotation that proteolytic enzymes need at their active site. Appending Pro-Gly-Pro therefore converts a fragile tetrapeptide into something that survives long enough to be studied. The same approach, from the same institute, produced Semax from an ACTH fragment.
Research material referenced
Selank 10mg, third-party HPLC tested
The mechanism that distinguishes it
The most specific reported activity is not receptor binding at all. Selank has been reported to inhibit enkephalin-degrading enzymes, extending the half-life of the body's own enkephalins rather than acting as an opioid ligand itself. Work from 2001 and 2002 in the Bulletin of Experimental Biology and Medicine measured this directly on plasma enkephalinase activity.
Other reported activity
Published work also describes effects on GABAergic signalling, on serotonergic and dopaminergic transmission, and on brain-derived neurotrophic factor expression. A 2008 study reported that intranasally administered Selank regulates BDNF expression in the rat hippocampus. As with Semax, the great majority of this is rodent work.
The evidence base, described accurately
PubMed indexes roughly 135 Selank records, a smaller literature than its parent peptide tuftsin, which has around 690. The mechanistic work appears in international journals; the clinical work is concentrated in Russian-language publications, principally the Korsakov Journal of Neurology and Psychiatry. That is a description of where the evidence sits, not a dismissal of it.
Regulatory position
Selank has a registration history in the Russian Federation. It holds no marketing authorisation from the MHRA, EMA or FDA, cannot be prescribed or dispensed in the UK, and is supplied here for laboratory research only. A registration granted by one national regulator confers nothing in any other jurisdiction.
Frequently asked questions
Is Selank approved in the UK?
No. It has a Russian registration history but holds no MHRA, EMA or FDA authorisation, and is supplied for laboratory research only.
What is Selank made from?
Tuftsin, a tetrapeptide from immunoglobulin G, with a Pro-Gly-Pro extension appended for stability.
Is Selank an opioid?
No. Reported work describes it slowing the breakdown of the body's own enkephalins by inhibiting enkephalin-degrading enzymes, rather than binding opioid receptors itself.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubChemPubChem · Selank (CID 11765600)pubchem.ncbi.nlm.nih.gov
- PubMedZozulya AA et al., Inhibitory effect of Selank on enkephalin-degrading enzymes. Bull Exp Biol Med 2001 (PMID 11550013)pubmed.ncbi.nlm.nih.gov
- PubMedInozemtseva LS et al., Intranasal Selank regulates BDNF expression. Dokl Biol Sci 2008 (PMID 18841804)pubmed.ncbi.nlm.nih.gov
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More Selank (Tuftsin Analogue) articles
- Selank's Enkephalinase MechanismSelank does not bind opioid receptors. Reported work shows it inhibits enkephalin-degrading enzymes, extending the half-life of the body's own enkephalins.
- Selank and GABAergic SignallingSelank has been reported to affect GABA-A receptor expression without binding the receptor directly - a different mechanism from benzodiazepines.
- Selank Storage, Stability and ReconstitutionSelank has no cysteine and no methionine, so the two usual degradation routes do not apply. What that changes about handling, and what it does not.
- Selank in the Published LiteratureAbout 135 indexed PubMed records, against 690 for its parent peptide tuftsin. How the mechanistic and clinical literatures split, and how to read them.